Incyte Q4 Earnings Call Highlights

Jakafi delivered fourth quarter sales of $828 million (up 7% ) and full-year sales of $3.093 billion (up 11% ). Bill said prescriptions increased 11% in the fourth quarter and 9% for the full year despite competition, with demand up across all three indications. He added that polycythemia vera (PV) is expected to be the “largest and fastest growing indication” in 2026, citing an estimated PV penetration rate of about 30% compared with 60%–70% in frontline myelofibrosis (MF). Formulary coverage was described ...